Therapicon's scientific expertise and proprietary technologies platforms are focused on developing innovative medicines designed to improve clinical outcomes through better efficacy and improved safety and on bringing new medications to patients that offer more than enhanced compliance or convenience, but also helping them lead better lives.
Our products pipeline is unique and very promising. We are continuing to invest in our proprietary portfolio in therapeutic areas as diverse as cancer immunological prevention and control, influenza viruses (types A and B), osteoporosis, HIV infections and cognitive dysfuntions.
The combination to develop and license final-stage products to some of the world's best pharmaceutical companies and to continue the partnered manufacture of the medicinal products currently on the market in some leading countries, the synthesis of some special API's, still continues to represent the main company turn-over.
We are passionate and enthusiastic about our goal and highly optimistic about our future in view of the exciting pipeline at different stages of development.
We welcome your interest.
Paolo Alberto Veronesi, CEO and R&D Director
Therapicon® is a registered trade-mark in Italy and at OMPI (WIPO)-Geneva